FOXP3 and leukemia: Further research supports the idea that HMAs post-HSCT can reduce GVHD while preserving the graft-versus-leukemia (GVL) effect, primarily by promoting the expansion of regulatory T cells and increasing FOXP3+ Tregs (34, 35).